Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.
Colonial War Memorial Hospital, Suva, Fiji.
J Glob Antimicrob Resist. 2022 Sep;30:286-293. doi: 10.1016/j.jgar.2022.06.016. Epub 2022 Jun 20.
There are scant primary clinical data on antimicrobial resistance (AMR) burden from low- and middle-income countries (LMICs). We adapted recent World Health Organization methodology to measure the effect of third-generation cephalosporin resistance (3GC-R) on mortality and excess length of hospital stay in Fiji.
We conducted a prospective cohort study of inpatients with Enterobacterales bloodstream infections (BSIs) at Colonial War Memorial Hospital, Suva. We used cause-specific Cox proportional hazards models to estimate the effect of 3GC-R on the daily risk (hazard) of in-hospital mortality and being discharged alive (competing risks), and we used multistate modelling to estimate the excess length of hospital stay.
From July 2020 to February 2021 we identified 162 consecutive Enterobacterales BSIs; 3GC-R was present in 66 (40.7%). Crude mortality for patients with 3GC-susceptible and 3GC-R BSIs was 16.7% (16/96) and 30.3% (20/66), respectively. 3GC-R was not associated with the in-hospital mortality hazard rate (adjusted hazard ratio [aHR] 1.13, 95% confidence interval [CI] 0.51-2.53) or being discharged alive (aHR 0.99, 95% CI 0.65-1.50), whereas Charlson comorbidity index score (aHR 1.62, 95% CI 1.36-1.93) and Pitt bacteraemia score (aHR 3.57, 95% CI 1.31-9.71) were both associated with an increased hazard rate of in-hospital mortality. 3GC-R was associated with an increased length of stay of 2.6 days (95% CI 2.5-2.8). 3GC-R was more common among hospital-associated infections, but genomics did not identify clonal transmission.
Patients with Enterobacterales BSIs in Fiji had high mortality. There were high rates of 3GC-R, which was associated with increased hospital length of stay but not with in-hospital mortality.
来自中低收入国家(LMICs)的抗菌药物耐药性(AMR)负担的初级临床数据很少。我们采用了最近世界卫生组织的方法,来衡量第三代头孢菌素耐药(3GC-R)对斐济血流感染(BSI)患者死亡率和住院时间延长的影响。
我们对苏瓦殖民战争纪念医院住院的肠杆菌科血流感染患者进行了前瞻性队列研究。我们使用特定于病因的 Cox 比例风险模型来估计 3GC-R 对住院期间死亡率和存活出院(竞争风险)的每日风险(危害)的影响,我们使用多状态模型来估计住院时间延长。
从 2020 年 7 月至 2021 年 2 月,我们确定了 162 例连续的肠杆菌科 BSI;其中 66 例(40.7%)存在 3GC-R。3GC-敏感和 3GC-R BSI 患者的粗死亡率分别为 16.7%(16/96)和 30.3%(20/66)。3GC-R 与住院期间死亡率的危害比(调整危害比[aHR]1.13,95%置信区间[CI]0.51-2.53)或存活出院(aHR 0.99,95%CI 0.65-1.50)无关,而 Charlson 合并症指数评分(aHR 1.62,95%CI 1.36-1.93)和 Pitt 菌血症评分(aHR 3.57,95%CI 1.31-9.71)均与住院期间死亡率的危害比增加有关。3GC-R 与住院时间延长 2.6 天相关(95%CI 2.5-2.8)。医院相关感染中 3GC-R 更为常见,但基因组学并未发现克隆传播。
斐济肠杆菌科 BSI 患者死亡率较高。3GC-R 发生率较高,与住院时间延长有关,但与住院期间死亡率无关。